Ptc Therapeutics (PTCT) Free Cash Flow (2012 - 2026)

Ptc Therapeutics' Free Cash Flow history runs 15 years deep, the most recent figure standing at -$60.2 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 106.94% year-over-year to -$60.2 million; the TTM figure through Mar 2026 stood at -$226.3 million (down 132.35% YoY), while the FY2025 annual figure was $702.3 million, up 751.77% from the prior year.
• Free Cash Flow was -$60.2 million for Q1 2026 at Ptc Therapeutics, down from -$36.6 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $868.4 million in Q1 2025 to a low of -$174.6 million in Q4 2022.
• Historically, Free Cash Flow has averaged -$2.4 million across 5 years, with a median of -$59.6 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Free Cash Flow slumped 353.55% in 2024, then surged 1319.55% in 2025.
• A 5-year view of Free Cash Flow shows it stood at -$174.6 million in 2022, then jumped by 39.37% to -$105.9 million in 2023, then soared by 74.17% to -$27.3 million in 2024, then slumped by 34.05% to -$36.6 million in 2025, then tumbled by 64.38% to -$60.2 million in 2026.
• The last three Free Cash Flow figures came in at -$60.2 million (Q1 2026), -$36.6 million (Q4 2025), and -$69.7 million (Q3 2025), per Business Quant data.